Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

5f-PB-22

This article is a stubmissing:
Pharmacology
Interactions
Tolerance
History & Culture
Legality
5f-PB-22 molecule structure5f-PB-22 molecule structure

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold1 mg
Light1-3 mg
Moderate3-5 mg
Strong5-8 mg
Heavy8+ mg

Due to the limited pharmacological data available for this compound, users should begin with the lowest possible dose and increase gradually to assess individual sensitivity.

Duration

Onset5-10 minutes
After Effects30-60 minutes
Total60-90 minutes

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Perception of increased weight or Perception of decreased weightIncreased heart rate

Cognitive

Visual

Auditory

Forked from Subjective Effect Documentation work byJosie Kins September 2015.

Reagent Testing

Expected colorimetric results for common reagent tests. Colors show reaction change over 1–2 minutes.

Marquis(MQ)
white → orange2
Mecke(ME)
white → brown2
Mandelin(MD)
yellow2 → green3 → brown3
Liebermann(LB)
white → brown3
Powered by PROtestkit.eu

Pharmacology

Pharmacology not written up yet

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance not written up yet

Harm Potential

Toxicity

Lethal Dosage

Several deaths have been associated with the use of 5F-PB-22, leading to its Schedule I classification in the United States in January 2014.

History & Culture

History & Culture not written up yet

Legality

Legality not written up yet

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes7 human edits · latest

Times are UTCNewest first

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  7. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 5f-PB-22 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.